Safety and Benefit of Using Probiotics in Patients Undergoing HSCT: Integrative Review

• Autor(a) principal: Dantas Pinheiro de Oliveira, Paola
• Data de Publicação: 2020
• Outros Autores: Johnsson Campos, Denise, Araújo Moreira Funke, Vaneuza, Mehl Coradi, Sarah, Vilela, Regina Maria
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/14
• topic: Probióticos; Transplante de Células-Tronco Hematopoéticas; Hospedeiro Imunocomprometido; Microbioma Gastrointestinal; Imunidade; Probiotics; Hematopoietic Stem Cell Transplantation; Immunocompromised Host; Gastrointestinal Microbiome; Immunity; Probióticos; Trasplante de Células Madre Hematopoyéticas; Huésped Inmunocomprometido; Microbioma Gastrointestinal; Inmunidad

Introduction: Hematopoietic stem cell transplantation (HSCT) is one of the potential curative treatments used for patients with hematological and other immune diseases. During transplantation, the patient undergoes conditioning and other treatments, such as radiotherapy and chemotherapy, which may cause loss of the intestinal microbiota diversity. The manipulation of the intestinal microbiota with probiotics has been pointed out as a strategy to prevent complications in patients undergoing HSCT. Objective: To identify if there is scientific evidence related to the safety and benefits of the use of probiotics in patients submitted to HSCT. Method: Integrative review based on studies addressing the use of probiotics for the specific case of patients undergoing HSCT published between 2000 and 2018. Results: Five studies that met the inclusion and exclusion criteria were eligible, with a total of 52 patients. The use of probiotics in the prevention and/or treatment of diarrhea has shown positive results in patients with antibiotic-induced diarrhea or bacterial infections, but the studies do not yet emphasize the benefits of using probiotics in the specific case of patients submitted to HSCT. Few studies show the use of probiotics to help the improvement of the symptoms associated to infections or bacteremia in immunosuppressed patients. Conclusion: The use of probiotics in the population submitted to HSCT and immunosuppressed is still controversial, and further studies are necessary to demonstrate the benefits of using probiotics for this public.